Adam Lerner, MD

Professor, Pathology & Laboratory Medicine

Adam Lerner
650 Albany St Evans Biomed Research Ctr


Expertise includes: CLL; Leukemia; Lymphoid malignancies; Sarcoma; Breast cancer; cAMP signaling.

Other Positions

  • Professor, Hematology & Medical Oncology, Medicine, Boston University School of Medicine
  • Member, BU-BMC Cancer Center, Boston University
  • Member, Evans Center for Interdisciplinary Biomedical Research, Boston University
  • Graduate Faculty (Primary Mentor of Grad Students), Boston University School of Medicine, Graduate Medical Sciences
  • Member, Genome Science Institute, Boston University


  • Yale University School of Medicine, MD
  • Amherst College, AB

Classes Taught

  • GMSMM703


  • Published on 7/18/2020

    Prilutskiy A, Kritselis M, Shevtsov A, Yambayev I, Vadlamudi C, Zhao Q, Kataria Y, Sarosiek SR, Lerner A, Sloan JM, Quillen K, Burks EJ. SARS-CoV-2 Infection-Associated Hemophagocytic Lymphohistiocytosis. Am J Clin Pathol. 2020 Jul 18. PMID: 32681166.

    Read at: PubMed
  • Published on 5/27/2020

    Dennis M, Maoz A, Cirstea D, Patel A, Lerner A, Sarosiek S. Treatment disparities in minority groups with multiple myeloma at a safety-net hospital. Leuk Lymphoma. 2020 May 27; 1-4. PMID: 32460648.

    Read at: PubMed
  • Published on 1/31/2019

    Leiva O, McMahon L, Sloan JM, Lee J, Lerner A. Recognition of hemophagocytic lymphohistiocytosis in sickle cell vaso-occlusive crises is a potentially lifesaving diagnosis. Haematologica. 2019 04; 104(4):e167-e169. PMID: 30705096.

    Read at: PubMed
  • Published on 1/15/2018

    Min MS, Al-Haseni A, Succaria F, Goldberg L, Lerner A, Sahni D. Anaplastic large cell lymphoma localized to the left breast years after radiotherapy for breast cancer. Dermatol Online J. 2018 Jan 15; 24(1). PMID: 29469762.

    Read at: PubMed
  • Published on 9/1/2017

    de Medeiros AS, Wyman AR, Alaamery MA, Allain C, Ivey FD, Wang L, Le H, Morken JP, Habara A, Le C, Cui S, Lerner A, Hoffman CS. Identification and characterization of a potent and biologically-active PDE4/7 inhibitor via fission yeast-based assays. Cell Signal. 2017 Dec; 40:73-80. PMID: 28867658.

    Read at: PubMed
  • Published on 8/30/2017

    Duvic M, Bates SE, Piekarz R, Eisch R, Kim YH, Lerner A, Robak T, Samtsov A, Becker JC, McCulloch W, Waksman J, Whittaker S. Responses to romidepsin in patients with cutaneous T-cell lymphoma and prior treatment with systemic chemotherapy. Leuk Lymphoma. 2018 04; 59(4):880-887. PMID: 28853310.

    Read at: PubMed
  • Published on 8/10/2016

    Foss F, Duvic M, Lerner A, Waksman J, Whittaker S. Clinical Efficacy of Romidepsin in Tumor Stage and Folliculotropic Mycosis Fungoides. Clin Lymphoma Myeloma Leuk. 2016 Nov; 16(11):637-643. PMID: 27637428.

    Read at: PubMed
  • Published on 6/13/2016

    Xu C, Wyman AR, Alaamery MA, Argueta SA, Ivey FD, Meyers JA, Lerner A, Burdo TH, Connolly T, Hoffman CS, Chiles TC. Anti-inflammatory effects of novel barbituric acid derivatives in T lymphocytes. Int Immunopharmacol. 2016 Sep; 38:223-32. PMID: 27302770.

    Read at: PubMed
  • Published on 10/13/2015

    Dong H, Carlton ME, Lerner A, Epstein PM. Effect of cAMP signaling on expression of glucocorticoid receptor, Bim and Bad in glucocorticoid-sensitive and resistant leukemic and multiple myeloma cells. Front Pharmacol. 2015; 6:230. PMID: 26528184.

    Read at: PubMed
  • Published on 5/20/2015

    Kim EJ, Kim YH, Rook AH, Lerner A, Duvic M, Reddy S, Robak T, Becker JC, Samtsov A, McCulloch W, Waksman J, Whittaker S. Clinically significant responses achieved with romidepsin across disease compartments in patients with cutaneous T-cell lymphoma. Leuk Lymphoma. 2015; 56(10):2847-54. PMID: 25791237.

    Read at: PubMed

View 66 more publications: View full profile at BUMC

View all profiles